Biogen to acquire RayThera in deal valued up to $1B

Biogen to acquire RayThera in deal valued up to $1B
Apellis surges on $5.6B buyout deal with Biogen
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
Sage Therapeutics rejects Biogen bid, starts strategic review
Sage sues Biogen in wake of $469M buyout offer: report
Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment
37.34BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US09062X1037
CUSIP
449370105
Sector
Healthcare
Industry
Drug Manufacturers - General
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
43.35
PEG Ratio
2.61
Book Value
127.61
Dividend Share
-
Dividend Yield
-
Earnings Share
5.63
Wall Street Target Price
254.17
EPS Estimate Current Year
12.44
EPS Estimate Next Year
16.37
EPS Estimate Current Quarter
1.9779
EPS Estimate Next Quarter
3.2676
Most Recent Quarter
-
Revenue TTM
10,027,899,904
Gross Profit TTM
7,854,099,968
EBITDA
3,359,200,000
Profit Margin
8.32%
Return On Assets TTM
5.21%
Return On Equity TTM
4.58%
Revenue Per Share TTM
68.194
Qtly Revenue Growth YOY
3.40%
Diluted Eps TTM
5.63
Qtly Earnings Growth YOY
-84.80%
Trailing PE
43.35
Forward PE
15
Price Sales TTM
3.5959
Price Book MRQ
1.9812
Enterprise Value Revenue
4
Enterprise Value EBITDA
20
160.00
6.58%1345.00
4.05%160.95
3.22%144.30
2.49%292.49
2.25%173.04
2.16%276.72
1.99%474.90
0.00%60.22
-0.25%480.00
-0.13%Curated watchlists where BIIB is featured.